Exenatide Reduces Inflammatory Markers That Insulin and Pioglitazone Do Not in New Type 2 Diabetes Patients
In a 416-patient multicenter RCT, exenatide uniquely reduced inflammatory cytokines IL-1β and IFN-γ over 48 weeks in newly diagnosed type 2 diabetes, while insulin actually increased them and pioglitazone had no effect.
Quick Facts
What This Study Found
Exenatide significantly decreased IL-1β and IFN-γ levels over 48 weeks, while insulin increased both markers. The anti-inflammatory effect of exenatide was independent of changes in weight, waist circumference, and HbA1c, and was associated with improved insulin resistance.
Key Numbers
416 patients from 25 centers. 48-week intervention. Three treatment arms compared for adipokine and inflammatory cytokine changes.
How They Did This
Post-hoc analysis of the CONFIDENCE trial: 416 newly diagnosed T2DM patients from 25 centers randomized to 48-week treatment with exenatide, insulin, or pioglitazone. Adipokines (leptin, FGF21) and inflammatory cytokines (IL-1β, IFN-γ) measured at baseline and study end.
Why This Research Matters
Chronic low-grade inflammation drives many complications of type 2 diabetes. This large RCT shows that exenatide has anti-inflammatory properties beyond blood sugar control — a benefit that insulin and pioglitazone do not share, potentially favoring GLP-1 drugs as first-line therapy.
The Bigger Picture
The anti-inflammatory effects of GLP-1 receptor agonists may partly explain their cardiovascular and organ-protective benefits observed in large outcome trials. This study adds mechanistic evidence that GLP-1 drugs do more than lower blood sugar — they may actively reduce the inflammatory environment that drives diabetic complications.
What This Study Doesn't Tell Us
Post-hoc analysis — adipokine changes were not the primary trial endpoint. Chinese population only, limiting generalizability. Exenatide is an older, less potent GLP-1 agonist; newer drugs like semaglutide may show different patterns. 32% dropout rate over 48 weeks.
Questions This Raises
- ?Do newer GLP-1 agonists like semaglutide and tirzepatide produce even stronger anti-inflammatory effects than exenatide?
- ?Could the inflammatory cytokine increase seen with insulin therapy contribute to worse long-term outcomes?
- ?Would combining exenatide with pioglitazone produce additive anti-inflammatory and insulin-sensitizing effects?
Trust & Context
- Key Stat:
- 416 patients, 25 centers Large multicenter RCT showing exenatide reduced inflammation while insulin increased it over 48 weeks
- Evidence Grade:
- Moderate-to-strong evidence — post-hoc analysis of a well-designed, large multicenter RCT, but adipokine endpoints were not the primary outcome.
- Study Age:
- Published in 2024 as a secondary analysis of the CONFIDENCE trial, reflecting current understanding of GLP-1 agonist anti-inflammatory effects.
- Original Title:
- Comparison of changes in adipokine and inflammatory cytokine levels in patients with newly diagnosed type 2 diabetes treated with exenatide, insulin, or pioglitazone: A post-hoc study of the CONFIDENCE trial.
- Published In:
- Heliyon, 10(1), e23309 (2024)
- Authors:
- Yang, Xubin, Deng, Hongrong, Lv, Jing, Chen, Xueyan, Zeng, Longyi, Weng, Jianping, Liang, Hua, Xu, Wen
- Database ID:
- RPEP-09594
Evidence Hierarchy
Frequently Asked Questions
Does exenatide reduce inflammation better than newer GLP-1 drugs like semaglutide?
This study only tested exenatide. While semaglutide and tirzepatide are more potent for blood sugar and weight, their comparative anti-inflammatory effects have not been directly measured in a head-to-head trial with the same cytokine panel.
Should I be concerned that insulin increased inflammatory markers?
The insulin-treated group showed increases in IL-1β and IFN-γ, but this doesn't mean insulin is harmful — it effectively controls blood sugar. The finding suggests that GLP-1 drugs may offer additional anti-inflammatory benefits that insulin does not, which could matter for long-term outcomes.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09594APA
Yang, Xubin; Deng, Hongrong; Lv, Jing; Chen, Xueyan; Zeng, Longyi; Weng, Jianping; Liang, Hua; Xu, Wen. (2024). Comparison of changes in adipokine and inflammatory cytokine levels in patients with newly diagnosed type 2 diabetes treated with exenatide, insulin, or pioglitazone: A post-hoc study of the CONFIDENCE trial.. Heliyon, 10(1), e23309. https://doi.org/10.1016/j.heliyon.2023.e23309
MLA
Yang, Xubin, et al. "Comparison of changes in adipokine and inflammatory cytokine levels in patients with newly diagnosed type 2 diabetes treated with exenatide, insulin, or pioglitazone: A post-hoc study of the CONFIDENCE trial.." Heliyon, 2024. https://doi.org/10.1016/j.heliyon.2023.e23309
RethinkPeptides
RethinkPeptides Research Database. "Comparison of changes in adipokine and inflammatory cytokine..." RPEP-09594. Retrieved from https://rethinkpeptides.com/research/yang-2024-comparison-of-changes-in
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.